Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.89M$2.89Mderived−1.4% vs Q4 2020 Net Income-$980.72K-$980.72KderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$301,936−46.2% Operating Incomederived-$648,690N/M Operating Cash Flowderived-$198,112N/M Free Cash Flowderived-$205,168N/M Margins · derivedGross margin10.4%−8.7 pt vs Q4 2020
Operating margin-22.5%+15.1 pt vs Q4 2020
Net margin-33.9%+7.3 pt vs Q4 2020
ended Dec 31, 2021 · filed Mar 30, 2022 · 89 d after period end